AstraZeneca Pharma India Ltd. — Earnings Release 2026

Nov 7, 2025

==> picture [503 x 53] intentionally omitted <==

November 7, 2025

The Manager – Listing BSE Limited 1[st] Floor, New Trading Ring Rotunda Building, P J Towers, Dalal Street, Fort, Mumbai 400001

The Manager – Listing National Stock Exchange of India Ltd. Exchange Plaza, 5[th] Floor, Plot No. C/1, G Block Bandra-Kurla Complex, Bandra (E), Mumbai 400051

Dear Sir(s),

Sub: Press Release

Ref: Scrip Code - BSE: 506820 / NSE: ASTRAZEN

Please find enclosed the press release for the unaudited financial results for the quarter ended September 30, 2025.

Thanking you,

For AstraZeneca Pharma India Limited

Digitally signed MANAS by MANASA RAMA A RAMA Date: 2025.11.07 18:12:37 +05'30'

Manasa. R Company Secretary

==> picture [452 x 64] intentionally omitted <==

News Release

==> picture [112 x 36] intentionally omitted <==

AstraZeneca Pharma India Limited marks 37% growth as the Company announces Q2 results

Revenue rises 37% in Q2 2025-26; seven new approvals in H1 reinforcing our leadership across therapy areas

Bengaluru, November 07, 2025: AstraZeneca Pharma India Limited (“the Company”), a science-led biopharmaceutical company, announced financial results for the quarter ended September 30, 2025. The Company delivered revenue growth of 37% in Q2 FY2025–26, reflecting disciplined execution and momentum across Oncology, Biopharmaceuticals (CVRM, R&I, V&I), and Rare Disease.

Financial performance Summary:

				(Value in INR Mn)
Summary	Q2 2025Jul -Sept’25	H1 2025Apr’25-Sep’25	Q2 2024Jul24-Sep’24	H1 2024Apr’24-Sep’24
Total revenue fromOperatons	5,590.9	10,854.0	4,080.0	7,955.2
Proft beforeexceptonal item andtax	781.1	1531.7	510.3	934.3
Proft afer exceptonalitem and tax	542.2	1100.5	384.3	266.4
Oncology	3,977.5	7,673.6	2,677.5	5,071.7
Biopharmaceutcals(CVRM, R&I and V&I)	1,267.5	2,457.5	1,180.9	2,444.2
Rare Disease	38.1	42.3	5.4	7.5

Bhavana Agrawal, Chief Financial Officer & Director of the Company, said, “Our strong Q2/H1 results reflect AstraZeneca’s strong growth trajectory and unwavering commitment to science-led progress. We continue to strengthen our leadership across therapy areas by advancing an innovation-first portfolio that delivers both patient impact and business value. Every approval and milestone underscore our focus on accelerating access to breakthrough treatments and driving sustainable, longterm growth.”

Praveen Akkinepally, Country President & Managing Director, AstraZeneca Pharma India Ltd. , added, “Our performance this quarter/in H1, is a clear testament to AstraZeneca’s purpose in action, translating cutting-edge science into life-changing medicines for patients in India. As we scale across our therapy areas, our focus on innovation, partnerships, and patient-centricity is shaping a more accessible and outcomes-driven healthcare ecosystem. Our momentum reinforces our vision to transform healthcare delivery and set new benchmarks for scientific excellence in India.”

Key milestones:

• Durvalumab – endometrial cancer : Received regulatory approval from CDSCO to import for sale and distribution of Durvalumab solution for infusion for two additional indications. Durvalumab in combination with carboplatin and paclitaxel is now indicated for first-line treatment of adults with primary advanced or recurrent endometrial cancer who are candidates for systemic therapy; followed by maintenance treatment with Durvalumab in combination with Olaparib in endometrial cancer that is pMMR .

News Release

==> picture [112 x 36] intentionally omitted <==

• Durvalumab – muscle invasive bladder cancer (MIBC) : Received regulatory approval from CDSCO to import for sale and distribution of Durvalumab Solution for Infusion 120 mg/2.4 ml and 500 mg/10 ml for an additional indication as adjuvant treatment following radical cystectomy for adult patients with MIBC.

• Eculizumab – rare disease leadership : Launched Eculizumab , the first anti-complement therapy approved in India by CDSCO for the treatment of atypical Haemolytic Uremic Syndrome (aHUS) and Paroxysmal Nocturnal Hemoglobinuria (PNH) , marking a significant milestone in rare diseases.

• Osimertinib – NSCLC : Received regulatory approval to import for sale and distribution of Osimertinib tablets for an additional indication in combination with pemetrexed and platinumbased chemotherapy for the first-line treatment of patients with locally advanced or metastatic NSCLC with EGFR exon 19 deletions or exon 21 (L858R) substitution mutations.

• Trastuzumab deruxtecan – HER2 spectrum expansion : Received regulatory approval from CDSCO to import for sale and distribution of trastuzumab deruxtecan for an additional indication in HER2-low and HER2-ultralow metastatic breast cancer patients who have received at least one endocrine therapy in the metastatic setting.

• Osimertinib – NSCLC (stage III, monotherapy) : Gained CDSCO regulatory approval for an additional indication of Osimertinib as monotherapy for import for sale and distribution for the treatment of patients with locally advanced, unresectable (stage III) NSCLC with EGFR exon 19 deletions or exon 21 (L858R) substitution mutations whose disease has not progressed during or following platinum-based chemoradiation therapy.

• Benralizumab – EGPA : Received regulatory approval from CDSCO to import for sale and distribution of Benralizumab for an additional indication as an add-on treatment for adult patients with relapsing or refractory eosinophilic granulomatosis with polyangiitis (EGPA) .

Recognitions:

• ET HRWorld EX Awards 2025: AstraZeneca Pharma India awarded for Exceptional Employee Experience (Large Scale), recognizing our progress in I&D.

About AstraZeneca Pharma India Ltd

AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in four therapy areas - Oncology, Cardiovascular, Renal & Metabolism and Respiratory and Rare Disease. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Completing its 45 years in India, AstraZeneca Pharma India Limited is headquartered at Bengaluru, Karnataka in India and has a workforce of over 600 employees across the country committed to deliver great medicines to patients through innovative science and global excellence in development and commercialization. For more information, please visit our website: htps://www.astrazeneca.in/ or follow us on LinkedIn: AstraZeneca India.